Neumora Therapeutics (NASDAQ:NMRA) Releases Quarterly Earnings Results, Hits Estimates

Neumora Therapeutics (NASDAQ:NMRA) announced its quarterly earnings results on Tuesday. The company reported ($0.34) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.34), Briefing.com reports.

Neumora Therapeutics Trading Down 4.0 %

NASDAQ:NMRA opened at $9.42 on Thursday. The stock has a 50-day moving average price of $13.32 and a 200 day moving average price of $14.08. Neumora Therapeutics has a 12-month low of $8.82 and a 12-month high of $21.00.

Wall Street Analyst Weigh In

NMRA has been the subject of a number of research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 price target on shares of Neumora Therapeutics in a research note on Thursday, March 28th. JPMorgan Chase & Co. increased their target price on Neumora Therapeutics from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, March 18th. Finally, William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a research report on Friday, April 12th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $22.57.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.